base-metals-investing Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
base-metals-investing Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base-metals-investing Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
base-metals-investing Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
base-metals-investing Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
base-metals-investing Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
base-metals-investing Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
base-metals-investing Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
Cerrado Gold Announces Dial-In-Details for Management Conference Call to Discuss the Purported Unfavourable Opinion of the Environmental Impact Assessment for the Lagoa Salgada Project, Portugal
Bombardier Global 8000, World's Fastest Business Jet, Receives Certification from European Union Aviation Safety Agency
